Deltex Medical Group PLC Excellent Results from New Trial
09 June 2017 - 4:00PM
RNS Non-Regulatory
TIDMDEMG
Deltex Medical Group PLC
09 June 2017
9 June 2017
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
First randomised trial in thoracic surgery published: ODM more
than halves complications and reduces length of hospital stay by
two days
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), is pleased to announce the
publication of a new trial showing excellent results from using ODM
in thoracic surgery.
The results of the randomised controlled trial of 100 patients
undergoing lung surgery at the University of Freiburg in Germany
have been published online by the British Journal of Anaesthesia.
Vascular fluids and vaso-active drugs were administered during
surgery in accordance with Enhanced Recovery After Surgery ('ERAS')
Society recommended protocols.
Nine fewer ODM patients (six v 15) suffered post-operative
pulmonary complications and ODM patients had a two day shorter stay
in hospital (nine v 11 days).
This is the first published randomised controlled trial studying
ODM use during thoracic surgery.
Reference: Kaufmann et al. Oesophageal Doppler guided
goal-directed haemodynamic therapy in thoracic surgery - a single
centre randomized parallel-arm trial. BJA: 118 (6): 852-61
(2017).
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"This is excellent news for large numbers of patients undergoing
lung resection with one in five of them avoiding a dangerous, life
shortening, complication. The trial allows us to target thoracic
surgery on top of those other specific types of surgery where the
value of ODM has previously been demonstrated.
"In the NHS in England there are around 40,000 patients a year
undergoing higher risk thoracic procedures with a risk of
post-operative death within 30 days of 1% or higher and very few of
these have fluids or vaso-active drugs administered with the aid of
ODM."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Financial Public Relations
IFC Advisory 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary ODM is the only
technology to measure blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM which is proven
to reduce complications suffered by patients after surgery and save
hospitals the costs of treating those complications.
Deltex Medical's CardioQ-ODM+ platform also now provides
clinicians with two further advanced haemodynamic monitoring
technologies. High Definition Impedance Cardiography is an entirely
non-invasive monitoring technology which sets creates an electrical
field across the chest and measures the disruption to this field
when the heart pumps blood. Pulse Pressure Waveform Analysis uses
peripheral blood pressure signal analysis to give doctors
information on changes in the circulation and is particularly
suited to monitoring lower risk or haemodynamically stable
patients.
Company goal
Haemodynamic management is now becoming widely accepted as an
important major new medical modality. Consequently, the Company's
focus is on maximising value from the opportunities presented as
enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Company aims to provide clinicians
with a single platform, a 'haemodynamic workstation', which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's condition and skill and
expertise of the user. Doing this will enable the Company to
partner healthcare providers to support modern haemodynamic
management across the whole hospital.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,400 monitors installed in hospitals around the
world and around 700,000 patients have been treated to date using
Deltex Medical's single patient disposable products.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFPMMTMBJMTMR
(END) Dow Jones Newswires
June 09, 2017 02:00 ET (06:00 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024